JAMI VONDIELINGEN: Open Payments
NPI 1255972006 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 35 payments from 11 companies in 2025. Trend: 2023 $688 · 2024 $707 · 2025 $1,027
Food & beverage: $1,027
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $369 |
| AstraZeneca Pharmaceuticals LP | 6 | $318 |
| ABBVIE INC. | 5 | $113 |
| GlaxoSmithKline, LLC. | 5 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Organon LLC | 1 | $12 |
Products named: Ozempic, BEVESPI AEROSPHERE, BREZTRI, VRAYLAR, CAPLYTA, Rybelsus, TRELEGY ELLIPTA, LINZESS.
Industry payments across IN — which companies pay providers there.
